From October 18 to 20, 2024, the 2024 Jiangsu Hematology Physicians Association Academic Conference was held in Taizhou, Jiangsu Province, focusing on the standardized diagnosis and treatment of hematologic diseases. Organized by the Jiangsu Hematology Physicians Association and hosted by the Affiliated Taizhou People’s Hospital of Nanjing Medical University and The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People’s Hospital), the conference provided a high-level academic exchange platform. Hematology Frontier invited Dr. Jianyong Li, Chairman of the conference and a distinguished expert from Jiangsu Provincial People’s Hospital, to share his insights on the event’s key highlights and discuss the current and future directions of hematology in China.

CAR-T therapy and bispecific antibodies, two innovative immunotherapies, have shown significant efficacy in patients with relapsed/refractory multiple myeloma (RRMM). But how do these two therapies compare in clinical practice? Minimal Residual Disease (MRD) detection is an important tool for evaluating treatment response and prognosis in multiple myeloma (MM), but its application in clinical settings is still limited. How can MRD use be further promoted? At the recent European Society for Medical Oncology (ESMO) Congress 2024, two pivotal studies delved into these questions, sparking widespread attention. This article features insights from Dr. Zhen Cai of The First Affiliated Hospital of Zhejiang University School of Medicine on these studies.

Aplastic Anemia (AA), a type of bone marrow failure syndrome, is challenging to treat. While hematopoietic stem cell transplantation (HSCT) may offer a cure, it is hindered by donor availability and high risk. Medical treatments provide symptom relief but with limited efficacy and potential for relapse. At the recent 18th Annual Chinese Society of Hematology Conference, Dr. Rong Fu from Tianjin Medical University General Hospital presented valuable insights into immunosuppressive therapy (IST) for AA. Following the conference, Hematology Frontier invited Professor Fu to discuss China’s AA prevalence, diagnostic and treatment advancements, current IST options, and future management strategies.

The 11th Sino-French Hematology Academic Conference of the Chinese Medical Doctor Association attracted hundreds of domestic and international authoritative experts and scholars in the field of hematology to gather together. During the conference, "Hematology Frontier" specially invited Professor Eolia Brissot from Hôpital Saint-Antoine in Paris to share the latest explorations of non-chemotherapy strategies in the treatment of acute lymphoblastic leukemia.

The 5th Tianjin International Lymphoma Academic Conference, as an academic platform to promote international academic exchange and cooperation, has actively played its role as a bridge, facilitating in-depth exchange and cooperation in the field of international lymphoma. During the conference, "Hematology Frontier" specially invited Professor Owen O’Connor, President of the Lymphoma Alliance and from the University of Virginia Cancer Center, and Professor Zhengzi Qian from the Tianjin Medical University Cancer Hospital to engage in a dialogue between China and the rest of the world, reviewing the current status and latest advances in the treatment of relapsed/refractory peripheral T-cell lymphoma (R/R PTCL).

Recently, the 11th Sino-French Hematology Academic Conference of the Chinese Medical Doctor Association was successfully held in Tianjin, attracting hundreds of domestic and international authoritative experts and scholars in the field of hematology. During the conference, "Hematology Frontier" specially invited Dr. Norbert Claude Gorin from Hôpital Saint-Antoine in Paris, a member of the French National Academy of Medicine, and a foreign academician of the Chinese Academy of Engineering, to discuss the evolution of the role of autologous transplantation in the treatment of acute myeloid leukemia (AML) and the challenges and potential of immunotherapy in AML treatment.